| Literature DB >> 29740488 |
Bolin Sun1, Yongbin Lv2, Dong Xing2, Jianlin Li2.
Abstract
The imaging performance and clinical value of contrast-enhanced ultrasonography (CEUS) combined with CT in diagnosis of liver cancer were investigated. A total of 426 liver cancer patients treated in Yuhuangding Hospital (Yantai, China) from February 2011 to May 2016 were selected. Among them, 222 patients underwent CEUS examination, 204 patients underwent CT examination, and 102 patients underwent CEUS combined with CT examination. Sensitivity and specificity of the three methods were examined. CT showed a low density in 92.6% of patients (189 patients) and a high-low hybrid density in 6.4% (13 patients), with calcification seen in 2.5% of patients (5 patients) and bleeding in 3.4% (7 patients). Lesions: 76.5% (156 cases) of patients with multiple type, 23.5% (48 cases) with single type. CEUS showed overall enhancement in 53.2% patients (118 cases), heterogenous enhancement in 16.7% (37 cases), peripheral enhancement in 18.9% of patients (42 cases), necrosis of liquefaction in 11.3% (25 cases). In 65.3% (145 cases) of patients, the portal venous phase and the delayed phase showed a low enhancement, while 34.7% (77 cases) showed no enhancement. The sensitivity and specificity rates of CEUS combined with CT detection of liver cancer were 87.8, 88.2 and 94.1%, respectively. The ROC curve analysis showed that the sensitivity and specificity of CEUS in the diagnosis of liver cancer were 76.8 and 78.9%, respectively. The sensitivity and specificity of CT were 81.2 and 85.5%, respectively. The sensitivity and specificity of CEUS combined with CT were 90.4 and 92.7%, respectively. CEUS combined with CT detection can make-up for the deficiencies of each other and effectively improve the coincidence rate of liver cancer diagnosis, which can be used as an effective examination method for the diagnosis of liver cancer.Entities:
Keywords: clinical value; combined diagnosis; computed tomo-graphy; contrast-enhanced ultrasonography; liver cancer
Year: 2018 PMID: 29740488 PMCID: PMC5934724 DOI: 10.3892/ol.2018.8281
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Basic information of 426 patients (n, %).
| Parameters | CEUS group (n=222) | CT group (n=204) | CEUS+CT group (n=102) | F-value | P-value |
|---|---|---|---|---|---|
| Age (years) | 2.350 | 0.293 | |||
| <59 | 124 (55.9) | 119 (58.3) | 61 (59.8) | ||
| ≥59 | 98 (44.1) | 85 (41.7) | 41 (40.2) | ||
| Sex | 3.280 | 0.448 | |||
| Male | 184 (82.9) | 167 (81.9) | 87 (85.3) | ||
| Female | 38 (17.1) | 37 (18.1) | 15 (14.7) | ||
| Ethnicity | 3.185 | 0.485 | |||
| Han | 214 (96.6) | 199 (97.5) | 99 (97.1) | ||
| Others | 8 (3.6) | 5 (2.5) | 3 (2.9) | ||
| Marital status | 2.212 | 0.410 | |||
| Married | 207 (93.2) | 184 (92.2) | 89 (87.3) | ||
| Unmarried | 11 (5.0) | 18 (8.8) | 10 (9.8) | ||
| Widowed | 4 (1.8) | 2 (1.0) | 3 (2.9) | ||
| Living area | 3.038 | 0.455 | |||
| Countryside | 134 (60.4) | 119 (58.3) | 64 (62.7) | ||
| City | 88 (39.6) | 85 (41.7) | 38 (37.3) | ||
| Smoking index | 3.074 | 0.332 | |||
| <400 | 61 (27.5) | 59 (28.9) | 24 (23.5) | ||
| ≥400 - <800 | 77 (34.7) | 69 (33.8) | 37 (36.3) | ||
| ≥800 | 84 (37.8) | 76 (37.3) | 41 (40.2) | ||
| Drinking | 2.584 | 0.310 | |||
| No drinking or occasionally | 74 (33.3) | 51 (25.0) | 22 (21.6) | ||
| Often | 148 (66.7) | 153 (75.0) | 80 (78.4) |
CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
Clinical symptoms of 426 patients (n, %).
| Parameters | CEUS group (n=222) | CT group (n=204) | CEUS+CT group (n=102) | F-value | P-value |
|---|---|---|---|---|---|
| Pathological types | 3.249 | 0.327 | |||
| Block | 19 (8.6) | 17 (8.3) | 7 (6.9) | ||
| Large block | 39 (17.6) | 41 (20.1) | 16 (15.7) | ||
| Nodular | 81 (36.5) | 74 (36.3) | 43 (42.2) | ||
| Diffuse | 36 (16.2) | 29 (14.2) | 10 (9.8) | ||
| Small cancer | 6 (2.7) | 5 (2.5) | 3 (2.9) | ||
| T staging | 3.467 | 0.458 | |||
| TX | 1 (0.5) | 0 (0.0) | 1 (1.0) | ||
| T0 | 8 (3.6) | 7 (3.4) | 2 (2.0) | ||
| T1 | 25 (11.3) | 19 (9.3) | 14 (13.7) | ||
| T2 | 48 (21.6) | 40 (19.6) | 23 (22.5) | ||
| T3 | 62 (27.9) | 50 (24.5) | 22 (21.6) | ||
| T4 | 46 (20.7) | 37 (18.1) | 21 (20.6) | ||
| N staging | 2.277 | 0.390 | |||
| NX | 5 (2.3) | 3 (1.5) | 3 (2.9) | ||
| N0 | 97 (43.7) | 83 (40.7) | 41 (40.2) | ||
| N1 | 85 (38.3) | 75 (36.8) | 34 (33.3) | ||
| M staging | 2.915 | 0.379 | |||
| MX | 7 (3.2) | 5 (2.5) | 2 (2.0) | ||
| M0 | 90 (40.5) | 78 (38.2) | 33 (32.4) | ||
| M1 | 92 (41.4) | 79 (38.7) | 40 (39.2) | ||
| Clinical manifestations | 3.391 | 0.426 | |||
| Fever and edema | 42 (18.9) | 39 (19.1) | 22 (21.6) | ||
| Weight loss | 56 (25.2) | 47 (23.0) | 28 (27.5) | ||
| Bloating, nausea, vomiting | 39 (17.6) | 27 (13.2) | 17 (16.7) | ||
| Right upper quadrant dull pain | 74 (33.3) | 66 (32.4) | 39 (38.2) | ||
| Liver pain | 51 (23.0) | 59 (28.9) | 34 (33.3) | ||
| Jaundice | 86 (38.7) | 74 (36.3) | 44 (43.1) | ||
| Dyspnea | 124 (55.9) | 110 (53.9) | 56 (54.9) | ||
| Cavity effusion | 154 (69.4) | 139 (68.1) | 64 (62.7) |
CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
Dynamic enhanced scanning feature classification criteria.
| Classification | Criteria |
|---|---|
| Progressive enhancement | Mild enhancement in the margin of the lesion in arterial phase, obvious enhancement in portal venous phase |
| No significant enhancement | No obvious enhancement in the lesions or visible nodular enhancement at the edge |
| Marginal anadem-like enhancement | Visible anadem-like lesions observed at the edge of the lesions |
| Fast-in, fast-out enhancement | Obvious enhancement in arterial phase, lesion enhancement was significantly reduced in portal venous phase and delayed phase |
Accuracy of three diagnostic methods (n, %).
| Methods | Diagnosed | Misdiagnosed | Accuracy (%) |
|---|---|---|---|
| CEUS | 195 (87.8) | 27 (12.2) | 87.8 |
| CT | 180 (88.2) | 24 (11.8) | 88.2 |
| CEUS+CT | 96 (94.1) | 6 (5.9) | 94.1 |
| χ2 | 12.54 | 13.47 | 13.87 |
| P-value | 0.041 | 0.037 | 0.032 |
CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
ROC curve analysis.
| Methods | AUC | 95% CI | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| CEUS | 0.724 | 0.211–2.534 | 76.8 | 78.9 |
| CT | 0.784 | 0.617–1.232 | 81.2 | 85.5 |
| CEUS+CT | 0.846 | 0.146–4.643 | 90.4 | 92.7 |
| χ2 | 13.51 | 12.74 | ||
| P-value | 0.037 | 0.041 |
CI, confidence interval; CEUS, contrast-enhanced ultrasonography; CT, computed tomography.
Figure 1.ROC curve analysis. The sensitivity and specificity of CEUS in the diagnosis of liver cancer were 76.8 and 78.9%, respectively. The sensitivity and specificity of CT were 81.2 and 85.5%, respectively. The sensitivity and specificity of CEUS and CT were 90.4 and 92.7%, respectively. CEUS, contrast-enhanced ultrasonography; CT, computed tomography.